Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

immunocytokine NHS-IL2-LT

A fusion protein consisting of a mouse-human chimeric antibody directed against DNA released by necrotic tumor cells fused to two molecules of a genetically modified human interleukin-2 (IL-2) with potential antineoplastic activity. Upon administration, the antibody moiety of immunocytokine NHS-IL2-LT binds to DNA released by necrotic tumor cells located primarily at the core of necrotic solid tumors, delivering the IL-2 moiety. In turn, the IL-2 moiety of this agent activates the immune system to mount a cytotoxic T-lymphocyte response against nearby tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:interleukin-2 fusion protein MSB0010445
Foreign brand name:Selectikine
Abbreviation:Ch.14.18-IL2
Code name:EMD 521873
MSB0010445
NHS-IL2
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search